CatDex
Oncology
Pre-clinicalActive
Key Facts
About DexTech Medical
DexTech Medical is a clinical-stage biotech developing targeted cancer therapies using its proprietary GuaDex platform, a carbohydrate-drug-conjugate technology. The company's pipeline includes several drug candidates, most notably OsteoDex for prostate cancer, which appears to be in advanced clinical studies. With a lean operational model, patented technology, and a focus on urological oncology, DexTech aims to address significant unmet medical needs in cancer treatment, though it faces the typical high-risk, high-cost challenges of drug development.
View full company profileTherapeutic Areas
Other Oncology Drugs
| Drug | Company | Phase |
|---|---|---|
| Bi-XDC with PROTACs | Coherent Biopharma | IND-enabling |
| Bi-XDC with RPT | Coherent Biopharma | Early-stage |
| mRNA Anticancer Vaccine | Sunshine Biopharma | Preclinical Research |
| Biosimilar Bevacizumab | Organon (2) | Phase 3 |
| Biosimilar Pembrolizumab | Organon (2) | Phase 3 |
| BCL-2 Inhibitor Program | Vincerx Pharma | Preclinical |
| Not specified in provided content | 3Sbio | Various |
| Preclinical Projects | Zion Pharma | Preclinical |
| Attenukine Oncology Candidate | Teva | Phase 1 |
| XEMA Tumor Marker ELISA Kit | XEMA Group | Commercial |
| KRAS inhibitor | Risen Pharma Tech | Preclinical/Phase 1 |
| KEAP1 Activator Program | Vividion Therapeutics | Phase 1 |